Modelling a population with Barrett's oesophagus from oesophageal adenocarcinoma incidence data

References

• Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 1975; 70: 826–35
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 1987; 87: 301–12
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Smith RR, Cameron JL. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 1988; 19: 942–8
   PubMed Web of Science ®Google Scholar
• Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25: 982–93
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995; 109: 1541–6
   PubMed Web of Science ®Google Scholar
• Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049–53
   PubMed Web of Science ®Google Scholar
• Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94: 86–91
   PubMed Web of Science ®Google Scholar
• Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29: 645–54
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549–55
   PubMed Web of Science ®Google Scholar
• El-Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 2002;31:421–40, viii.
   PubMedGoogle Scholar
• El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002; 50: 368–72
   PubMedGoogle Scholar
• van Blankenstein M, Hop WCJ, Looman CWN, Bytzer P. The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus; Barrett's esophagus makes a difference. Am J Gastroenterol 2005; 100: 766–74
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 2000; 119: 333–8
   PubMed Web of Science ®Google Scholar
• Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331–8
   PubMed Web of Science ®Google Scholar
• van Blankenstein M, Looman CWN, Johnston BJ, Caygill CPJ. Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. Am J Gastroenterol 2005; 100: 568–76
   PubMed Web of Science ®Google Scholar
• van Soest EM, Siersema PD, Dieleman JP, Sturkenboom JMC, Kuipers EJ. Age and sex distribution of the incidence of Barrett's esophagus found in a Dutch primary care population. Am J Gastroenterol 2005; 100: 2599–600
   PubMedGoogle Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526–35
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918–22
   PubMed Web of Science ®Google Scholar
• Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825–31
   PubMed Web of Science ®Google Scholar
• van Blankenstein M, Hop WCJ, Looman CWN, Bytzer P. The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus; Barrett's esophagus makes a difference. Am J Gastroenterol 2005;100:766–74.
   PubMed Web of Science ®Google Scholar
• Dempster AP, Laird NM, Rubin DB. Maximal likelihood from incomplete data via the EM algorithm. J R Statist Soc B 1977; 39: 1–38
   Google Scholar
• Anonymous, Danish Statistical Yearbook 1992. Copenhagen:1992.
   Google Scholar
• GOSPE. Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE). Int J Cancer 1991; 48: 364–8
   PubMedGoogle Scholar
• Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241–5
   PubMed Web of Science ®Google Scholar
• Brown LM, Silverman DT, Pottern LM, Schoenberg JB, Greenberg RS, Swanson GM, et al. Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 1994; 5: 333–40
   PubMed Web of Science ®Google Scholar
• Nordling CO. A new theory on the cancer-inducing mechanism. Br J Cancer 1953; 7: 68–72
   PubMed Web of Science ®Google Scholar
• Armitage P, Doll R. The age distribution of cancer and multistage theory of carcinogenesis. Br J Cancer 1954; 8: 1–12
   PubMed Web of Science ®Google Scholar
• Heidenreich WF, Luebeck EG, Hazelton WD, Paretzke HG, Moolgavkar SH. Multistage models and the incidence of cancer in the cohort of atomic bomb survivors. Radiat Res 2002; 158: 607–14
   PubMed Web of Science ®Google Scholar
• Dulai GS. Surveying the case for surveillance. Gastroenterology 2002; 122: 820–3
   PubMedGoogle Scholar
• Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857–9
   PubMed Web of Science ®Google Scholar
• van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5–8
   PubMed Web of Science ®Google Scholar
• Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001; 48: 304–309
   PubMed Web of Science ®Google Scholar
• Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111: 33–7
   PubMedGoogle Scholar
• Anderson LA, Murray LJ, Murphy SJ, Fitzpatrick DA, Johnston BT, Watson RG, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003; 52: 1081–4
   PubMed Web of Science ®Google Scholar
• van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005; 54: 1062–6
   PubMed Web of Science ®Google Scholar
• Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 670–80
   PubMedGoogle Scholar
• Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043–53
   PubMed Web of Science ®Google Scholar
• Gudlaugsdottir S, van Blankenstein M, Dees J, Wilson JH. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol 2001; 13: 639–45
   PubMedGoogle Scholar
• Spechler SJ, Barr H. Review article: screening and surveillance of Barrett's oesophagus: what is a cost-effective framework?. Aliment Pharmacol Ther 2004; 19(Suppl 1)49–53
   PubMedGoogle Scholar
• Johansson S, Wallander MA, Ruigomez A, Garcia Rodriguez LA. Is there any association between myocardial infarction, gastro-oesophageal reflux disease and acid-suppressing drugs?. Aliment Pharmacol Ther 2003; 18: 973–8
   PubMed Web of Science ®Google Scholar
• Solaymani-Dodoran M, Logan RFA, West J, Card T. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses: a population based cohort study. Am J Gastroenterol 2005; 100: 2616–21
   PubMedGoogle Scholar
• Loffeld RJ, Werdmuller BF, Kuster JG, Perez-Perez GI, Blaser MJ, Kuipers EJ, et al. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000; 62: 95–9
   PubMed Web of Science ®Google Scholar
• Sharma P. Helicobacter pylori: a debated factor in gastroesophageal reflux disease. Dig Dis 2001; 19: 127–33
   PubMedGoogle Scholar
• Sharma VK, Crowell CWH. Infection with H. pylori or cag A+ H. pylori is protective against Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC): A meta-analysis. Gastroenterology 2004; 126: A–87
   Google Scholar
• Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96: 388–96
   PubMedGoogle Scholar
• Dworak O, Kuspert G. Re: Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995; 87: 847–48
   PubMedGoogle Scholar
• Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90: 150–5
   PubMed Web of Science ®Google Scholar
• Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883–90
   PubMed Web of Science ®Google Scholar
• Caygill CP, Johnston DA, Lopez M, Johnston BJ, Watson A, Reed PI, et al. Lifestyle factors and Barrett's esophagus. Am J Gastroenterol 2002; 97: 1328–31
   PubMedGoogle Scholar
• Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199–211
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005; 100: 2151–6
   PubMed Web of Science ®Google Scholar
• Spechler SJ. Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. Gastroenterology 2002; 122: 1518–20
   PubMed Web of Science ®Google Scholar
• Fletcher J, Wirz A, Young J, Vallance R, McColl KE. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775–83
   PubMed Web of Science ®Google Scholar
• Iijima K, Henry E, Moriya A, Wirz A, Kelman AW, McColl KE, et al. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 2002; 122: 1248–57
   PubMed Web of Science ®Google Scholar
• McColl KE. When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut 2005; 54: 1–3
   PubMed Web of Science ®Google Scholar
• Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929–34
   PubMed Web of Science ®Google Scholar
• Asanuma K, Iijima K, Sugata H, Ohara S, Shimosegawa T, Yoshimura T, et al. Diffusion of cytotoxic concentrations of nitric oxide generated luminally at the gastro-oesophageal junction of rats. Gut 2005; 54: 1072–7
   PubMed Web of Science ®Google Scholar
• Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249–56
   PubMed Web of Science ®Google Scholar
• Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607–19
   PubMed Web of Science ®Google Scholar
• Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989; 30: 14–8
   PubMedGoogle Scholar
• Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers J. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004; 39: 1175–9
   PubMed Web of Science ®Google Scholar
• Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 2004; 164: 1482–8
   PubMedGoogle Scholar
• Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825–31
   PubMed Web of Science ®Google Scholar
• Sabel MS, Pastore K, Toon H, Smith JL. Adenocarcinoma of the esophagus with and without Barrett mucosa. Arch Surg 2000;135:831–5; discussion 836.
   PubMedGoogle Scholar
• Azzopardi JG, Menzies T. Primary oesophageal adenocarcinoma. Confirmation of its existence by the finding of mucous gland tumours. Br J Surg 1962; 49: 497–506
   PubMed Web of Science ®Google Scholar
• Raphael HA, Ellis FH, Jr, Dockerty MB. Primary adenocarcinoma of the esophagus. Ann Surg 1966; 164: 785
   PubMed Web of Science ®Google Scholar
• Fabre A, Tansey DK, Dave U, Wright M, Teare JP, Rosin DR, et al. Adenocarcinoma in situ arising from the submucosal oesophageal mucous glands. Eur J Gastroenterol Hepatol 2003; 15: 1047–9
   PubMed Web of Science ®Google Scholar
• Aitkin M, Anderson D, Francis B, Hinde J. Statistical Modeling in GLIM. Clarendon Press, Oxford 1989
   Google Scholar